Tirofiban in percutaneous coronary intervention of patients with acute non-ST segment elevation myocardial infarct: Safety and efficacy

Academic Journal of Second Military Medical University

Volumn 28, Issue 5, 2007, Pages 524-526

  Li, Nan ^a   Zu, Xiao Lin ^a   Yan, Hong Bing ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Acute non ST segment elevation myocardial infarct; Percutaneous coronary intervention; Platelet glycoprotein II b III a inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PLACEBO; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSAL BLEEDING; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE THROMBOSIS; RANDOMIZED CONTROLLED TRIAL; SKIN BLEEDING; ST SEGMENT ELEVATION; STATISTICAL SIGNIFICANCE; THROMBOCYTOPENIA;

EID: 34249722034     PISSN: 0258879X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Ferguson J J, Zaqqa M. Platelet glycoprotein II b/III a receptor antagonists: current concepts and future direction [J]. Drugs, 1999,58:965-982.
2. Effects of platelet glycoprotein II b/III a blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE investigators. Randomized efficacy study of tirofiban for outcomes and restenosis[J]. Circulation,1997,96: 1445-1453.
3. Boersman E, Harrington R A, Moliterno D J, et al. Platelet glycoprotein II b/III a inhibitors in acute coronary syndromes a Meta-analysis of all major randomised clinical trials[J]. Lancet, 2002,359:189-198.
4. Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The ADVANCE Trial [J]. J Am Coll Cardiol,2004,44:14-19.
5. Kochman W, Dobrzycki S, Nowak K S, et al. Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty, a pilot study [J]. J Thromb Thrombolysis, 2004,17:127-131.
6. Juergens C P, White H D, Belardi J A, et al. A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement[J]. Clin Ther, 2002,24:1332-1344.
7. Montalescot G, Borentain M, Payot L, et al. Early vs late administration of glycoprotein II b/III a inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis[J]. JAMA, 2004, 292: 362-366.